CN110997710A - 靶向的蛋白降解 - Google Patents

靶向的蛋白降解 Download PDF

Info

Publication number
CN110997710A
CN110997710A CN201880057133.9A CN201880057133A CN110997710A CN 110997710 A CN110997710 A CN 110997710A CN 201880057133 A CN201880057133 A CN 201880057133A CN 110997710 A CN110997710 A CN 110997710A
Authority
CN
China
Prior art keywords
car
cell
protein
ubiquitin
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057133.9A
Other languages
English (en)
Chinese (zh)
Inventor
L.L.布雷绍
M.M.汉
C.赫林
C.马丁内斯弗莱特斯
M.A.奎瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN110997710A publication Critical patent/CN110997710A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880057133.9A 2017-07-03 2018-07-02 靶向的蛋白降解 Pending CN110997710A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1710620.4A GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation
GB1710620.4 2017-07-03
PCT/EP2018/067741 WO2019007869A1 (en) 2017-07-03 2018-07-02 TARGETED DEGRADATION OF PROTEINS

Publications (1)

Publication Number Publication Date
CN110997710A true CN110997710A (zh) 2020-04-10

Family

ID=59592357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057133.9A Pending CN110997710A (zh) 2017-07-03 2018-07-02 靶向的蛋白降解

Country Status (8)

Country Link
US (2) US10683360B2 (enExample)
EP (1) EP3649149A1 (enExample)
JP (1) JP7369039B2 (enExample)
CN (1) CN110997710A (enExample)
BR (1) BR112019028024A2 (enExample)
CA (1) CA3068365A1 (enExample)
GB (2) GB201710620D0 (enExample)
WO (1) WO2019007869A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112940096A (zh) * 2021-01-29 2021-06-11 西安交通大学 一种膀胱癌血清多肽标志物及其应用
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途
WO2022088291A1 (zh) * 2020-10-28 2022-05-05 北京大学深圳研究生院 选择性修饰靶标蛋白的基团转移方法及其应用
WO2022161502A1 (zh) * 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CN111107874A (zh) * 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
BR112020007576A2 (pt) * 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
US12049482B2 (en) * 2017-10-31 2024-07-30 The Brigham And Women's Hospital, Inc. Molecular switch-mediated control of engineered cells
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3908329A4 (en) * 2019-01-07 2022-12-07 The Regents of the University of California CAGE DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE THERE
KR20210112347A (ko) * 2019-01-07 2021-09-14 유니버시티 오브 워싱턴 단백질 분해의 조정 가능한 제어를 위한 단백질 스위치의 데노보 설계
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
US20220251152A1 (en) * 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
AU2020391285B2 (en) * 2019-11-27 2024-05-23 Onegene Biotechnology Inc. Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration
US20230114854A1 (en) * 2020-02-14 2023-04-13 Cellgentek Co., Ltd. Chimeric antigen receptor targeting b-cell maturation antigen and use thereof
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
CN116368152A (zh) * 2020-09-13 2023-06-30 山东博安生物技术股份有限公司 通过受体tac技术的膜结合蛋白的下调
NL2031325B1 (en) 2022-03-18 2023-09-29 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Novel zinc finger degron sequences
JP2025539386A (ja) 2022-12-01 2025-12-05 エー・テー・ハー・チューリッヒ 修飾アミノ酸デグロン（ｍａａｄ）を同定する方法
WO2025248464A2 (en) 2024-05-29 2025-12-04 Cell Control Biotherapeutics, Inc. Loop reinforcement expression system for improved cell therapy products
CN119699269B (zh) * 2024-07-10 2025-10-17 太原市中心医院 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322073A1 (en) * 2011-04-29 2012-12-20 Antonia Lopez-Girona Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CN103265635A (zh) * 2013-04-28 2013-08-28 中山大学附属第一医院 一种通用的靶向蛋白嵌合型分子化合物的构建方法
WO2016057903A1 (en) * 2014-10-10 2016-04-14 Dana-Farber Cancer Institute, Inc. Methods for discovering therapeutics that alter the stability of target proteins
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
CN106458993A (zh) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
WO2017044801A2 (en) * 2015-09-11 2017-03-16 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417344B1 (en) * 2001-08-17 2011-06-15 Toolgen, Inc. Zinc finger domain libraries
EP2818480B1 (en) * 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
US10830762B2 (en) * 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
ES2916335T3 (es) * 2016-10-20 2022-06-30 Celgene Corp Receptores de antígeno quimérico heterodimerizable basados en cereblon

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322073A1 (en) * 2011-04-29 2012-12-20 Antonia Lopez-Girona Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CN103265635A (zh) * 2013-04-28 2013-08-28 中山大学附属第一医院 一种通用的靶向蛋白嵌合型分子化合物的构建方法
CN106458993A (zh) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
WO2016057903A1 (en) * 2014-10-10 2016-04-14 Dana-Farber Cancer Institute, Inc. Methods for discovering therapeutics that alter the stability of target proteins
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017044801A2 (en) * 2015-09-11 2017-03-16 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATYSKIELA MARY E. ET AL: "A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 2, pages 535 - 542, XP002784904, DOI: 10.1021/acs.jmedchem.6b01921 *
PETZOLD G ET AL: "Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase", NATURE, vol. 532, pages 127 - 130 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022088291A1 (zh) * 2020-10-28 2022-05-05 北京大学深圳研究生院 选择性修饰靶标蛋白的基团转移方法及其应用
CN112940096A (zh) * 2021-01-29 2021-06-11 西安交通大学 一种膀胱癌血清多肽标志物及其应用
WO2022161502A1 (zh) * 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途

Also Published As

Publication number Publication date
GB2568987A (en) 2019-06-05
CA3068365A1 (en) 2019-01-10
BR112019028024A2 (pt) 2020-07-07
GB201710620D0 (en) 2017-08-16
US20190002578A1 (en) 2019-01-03
WO2019007869A1 (en) 2019-01-10
EP3649149A1 (en) 2020-05-13
JP2020529970A (ja) 2020-10-15
JP7369039B2 (ja) 2023-10-25
US11427643B2 (en) 2022-08-30
US20200283538A1 (en) 2020-09-10
US10683360B2 (en) 2020-06-16
GB201810814D0 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
US11427643B2 (en) Targeted protein degradation
TWI860971B (zh) 用於結合ａｘｌ之嵌合抗原受體、經分離之重組ｔ細胞、載體及在體外活化ｔ細胞的方法
TWI871269B (zh) 非複製勝任型重組反轉錄病毒顆粒
CA3054064A1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
ES2962588T3 (es) Proteínas de fusión de PD-1 y 4-1BB
WO2017064084A1 (en) Novel chimeric antigen receptors
CN114891751A (zh) 一种高效稳定表达激活型抗体的car-t细胞及其用途
WO2017219937A1 (zh) 一种高效稳定表达抑制性抗体的car-t细胞及其用途
US20220323494A1 (en) Novel Control Switch
CA3181394A1 (en) Chimeric antigen receptors targeting cd127 and use thereof
US20250197472A1 (en) Programmable immunocyte receptor complex system
CN119053618A (zh) 嵌合ilt受体组合物和方法
CN115397867A (zh) Epcam抗体与car-t细胞
CN115279407A (zh) 用于在哺乳动物中刺激嵌合抗原受体介导的免疫应答的方法中的包含pd-l1和/或pd-l2的靶向模块
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
TWI905076B (zh) 非複製勝任型重組反轉錄病毒顆粒及其用途
WO2024033544A1 (en) Deglycosylation of native glycoproteins expressed on a tumor cell surface
CN119529098A (zh) 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白
CN120548323A (zh) 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
CN116462769A (zh) 一种嵌合受体及其应用
HK1239732A1 (en) Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410

WD01 Invention patent application deemed withdrawn after publication